The buzz around Beyond Meat has been strong since the company's IPO last week, and subsequent 63% surge in stock price. Perhaps the warm reception has investors looking to uncover value in other, lesser-known plant-based protein stocks, as Burcon NutraScience Corp. (BU:TSX) has seen its own shares vault more than 53% on Monday, May 6th for a 5-day gain of 147%.
The company's most recent report of financial results state: "As at December 31, 2018, Burcon has not yet generated any significant revenues from its technology. For the three and nine months ended December 31, 2018, the company recorded a loss of $1,155,000 and $3,532,000 ($0.03 and $0.08 per share), respectively. . .The commercial success of any of Burcon's products will depend on whether they receive public and industry acceptance as a food ingredient and dietary supplement."
The company holds 66 U.S. patents for its extraction technologies and product uses, with an additional 45 under review by the United States Patent and Trademark Office. Burcon successfully commercialized CLARISOY, the company's flagship soy-based protein product, and is currently working to commercialize several other plant-based nutrition products, including Peazazz, Puratein, Supertein and Nutratein, each with a distinct functional and nutritional attribute.
Burcon NutraScience Corp. closed at $0.89 on May 6th, up from $0.36 on May 1st.
[NLINSERT]Disclosure:
1) Kevin Jaillet compiled this article for Streetwise Reports LLC and is an employee of Streetwise Reports. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
